Schulich school of Medicine and Dentistry logo Microbiology & Immunology Schulich Medicine & Dentistry

Welcome to the Kang Lab


Dr. C. Yong Kang (Dipl. Vet. Sci Denmark ; BSc Korea ; PhD McMaster; F.R.S.C. )

Office: Rm 129 Siebens-Drake Research Institute
Phone: 519 661-3226
Fax: 519 661-3499



Dr. Chil-Yong (Yong) Kang, PhD, DSc, FRSC, is a molecular virologist and Professor of Virology in the Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry at the University of Western Ontario in Canada (1992-Present).

He carried out his postgraduate studies at McMaster University where he received a Ph.D. in virology under the supervision of Professor Ludvik Prevec (1968-1971) and his postdoctoral training under Professor Howard Temin at the University of Wisconsin-Madison (1971-1974).

Dr. Kang went on to serve as a Professor of Virology in the Department of Microbiology at the University of Texas, Southwestern Medical School in Dallas, Texas (1974-1982), Professor and Chairman of the Department of Microbiology and Immunology at the University of Ottawa, Faculty of Medicine (1982-1992), and Dean of Science at the University of Western Ontario (1992-1999).

His research in molecular virology includes the development of viral-specific antiviral therapeutic agents and efficacious vaccines against various human viral diseases including AIDS, hepatitis and hemorrhagic fever with renal syndrome. Previously, he developed a second generation vaccine against hepatitis B virus and an experimental vaccine against HIV/AIDS by using state-of-the-art technologies of genetic engineering and biotechnology. Recently, his Phase I human clinical trial of SAV001 prophylactic HIV vaccine, based on genetically modified killed-whole HIV-1, was successfully completed and preparing for the Phase II trial. Dr. Kang has published 135 peer reviewed research papers and 149 scientific proceedings and abstracts in the fields of virology, Immunology, molecular biology, and medicine. He holds nine international biotechnology patents that cover over 70 countries.

Dr. Kang has received numerous prizes such as the Award of Excellence of the University of Ottawa (1991), Gold Medal for Ilchun Lecture (1998), Ho-Am Prize in Medicine (1999), the Order of Korea in Science and Technology (2002), the McMaster University Distinguished Alumni Award for 2007, the Lifetime Achievement Award from University of Western Ontario (2009), the Queen Elizabeth II Diamond Jubilee Medal (2012), selected as a Korean-Canadian Diaspora to Canadian Society by Canadian Government (2013) and the Scientist of the Year Award from the Korean Federation of Science and Technology (2013). Dr. Kang was elected as a Life-time Fellow of the Royal Society of Canada Academy of Science (1993) and an elected Life-time Member of the Korean Academy of Science and Technology (1997).

He continues to serve as a grant selection committee member for various federal granting agencies in Canada and the United States. He is a member of the Board of Directors of numerous research institutions and foundations. Dr. Kang also serves as a reviewer for the Journal of Virology, Journal of Infectious Diseases, Virus Research, Virology, Journal of Biological Chemistry, Journal of Human Virology and Retrovirology, and Canadian Medical Association Journal.

Recent Publications;

Kim, G. N. and Kang, C.-Y. Utilization of homotypic and heterotypic proteins of vesicular stomatitis virus by defective interfering particle genomes for RNA replication and virion assembly: Implications for the mechanism of  homologous viral interference.  Journal of Virology, 79: 9588-9596, 2005.

 Kim, G. N. and Kang, C.-Y. Matrix protein of VSV New Jersey serotype containing methionine to arginine substitution at positions 48 and 51 allows near-normal host cell gene expression. Virology, 341: 41-53, 2007

 Luo, L., Li, Y., Ha, S.D. and Kang, C.-Y. Hydrophilicity dependant budding and secretion of chimeric HIV Gag-V3 virus-like particles. Virus Genes, 35:187-193, 2007

 Wu, K, Kim, G. N., and Kang, C.-Y. Expression and processing of HIV-1 Env glycoprotein using vesicular stomatitis virus New Jersey serotype vector. J. of Gen. Virol.  90 (5): 1141-1147, 2009

 Kang, C.-Y.  HIV and AIDS Vaccine. The J. of Zoonoses 1: 33-37, 2010    

 Michalski, C. J., Li, Y., and Kang, C.-Y.  Induction of Cytopathic Effects and Apoptosis in Spodoptera frugiperda Cells by the HIV-1 Env Glycoprotein Signal Peptide, Virus Genes, 41: (3) 341-350, 2010

An, H., Kim, G.N., and Kang, C.-Y.  Genetically modified VSVNJ vector is capable of accommodating a large  foreign gene insert and allows high level gene expression, Virus Research, 171:168-177, 2013